Rapport Therapeutics RAPP Cash Flow Statement (2023-2026)

NASDAQ RAPP
$26.01 -0.06 (-0.21%)
As of: Nov 10, 2026 · 12:12 PM EST
Reported Financials

Rapport Therapeutics Quarterly Cash Flow Statement

Periods 14 quarters
Latest Sep 2026

Rapport Therapeutics reported cash from operations of -$41.63M and free cash flow of -$41.63M for the quarter ended Sep 2026, down 138.4% year over year. This cash flow statement covers 14 quarters of results from Jun 2023 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income -6.41M-8.71M-13.52M-22.67M-18.12M-17.54M-19.98M-24.06M-26.73M-26.93M-33.76M-19.86M-56.62M-40.24M
Depreciation and DepletionDep. & Depletion 0.10M0.02M0.04M0.20M0.20M0.20M0.20M0.20M0.30M0.30M0.20M0.20M0.20M0.20M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort. 0.10M0.02M0.05M0.15M0.21M0.22M0.26M0.24M0.25M0.26M0.27M0.23M0.21M0.20M
Share-based CompensationStock Comp. 0.95M0.86M1.00M1.49M2.35M3.18M3.21M4.04M4.39M4.74M5.69M6.96M7.20M7.63M
Other non-cash itemsOther Non-Cash 0.05M0.25M7.55M0.16M0.16M0.17M0.41M0.48M0.57M0.57M0.58M0.60M0.61M
Change in Working Capital
Change in ReceivablesChange Receivables 0.06M0.24M-0.12M
Change in Account PayablesChange Payables 0.63M0.73M-1.13M0.09M0.05M0.65M0.19M1.03M-0.18M1.18M2.31M-3.68M-1.09M
Change in Accrued ExpensesChange Accrued Exp. 1.11M3.38M0.18M-0.98M0.32M0.85M0.33M0.45M1.70M3.69M-3.49M14.58M-6.93M
Change in Other Operating AssetsOther Assets Change -0.53M2.00M2.04M-0.92M0.67M-0.02M0.88M4.82M-2.17M0.87M-1.16M3.16M0.86M
Change in Other Operating LiabilitiesOther Liabilities Change 0.16M0.16M0.17M0.17M0.18M0.07M0.04M-0.01M0.39M0.68M0.70M0.72M
Other Working Capital ChangesOther WC Changes 0.53M-1.84M-1.88M1.09M-0.50M0.20M-0.80M-4.78M2.16M-0.48M1.84M-2.46M-0.14M
Cash from OperationsCash from Ops. -5.42M-10.36M-17.62M-16.35M-16.42M-14.45M-20.24M-25.07M-17.47M-24.70M-13.06M-41.46M-41.63M
Investing Activities
Capital ExpendituresCapex 0.05M1.44M1.07M0.97M0.14M0.23M0.29M0.02M0.13M0.17M0.09M0.08M
Sales of Property, Plant and EquipmentPP&E (Sale) 0.21M
Change in Property, Plant and EquipmentChange in PP&E 0.21M
Purchase of InvestmentsInvestments Purchased 14.40M
Sale and Maturity of InvestmentsInvestments Sold 65.25M
Cash from Investing ActivitiesCash from Investing 51.06M
Financing Activities
Change in Capital Stock
Common Stock IssuedStock Issued 1.71M
Net Shares Issued and RepurchasedNet Shares Issued 1.71M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued 85.31M-81.31M
Net Equity Issued and RepurchasedNet Equity Issued 1.71M
Other financing activities (as filed) 0.00M
Cash from Financing ActivitiesCash from Financing 1.71M
Additional items
Change in Cash 11.14M
Ending Cash Balance 74.86M
Free Cash FlowFCF -41.63M
Net Cash FlowNCF 11.14M

Rapport Therapeutics Cash Flow Statement API

Pull Rapport Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=RAPP&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY